SangStat Commences Volume Manufacturing of TRANSTAT Technology
SangStat, a biopharmaceutical company, announced that it had commenced volume manufacturing of its TRANSTAT technology, a rapid cartridge-based testing system for haemostasis and coagulation testing. The company has licensed the rights to its TRANSTAT product technology to Diagnostica Stago S.A., a leading European manufacturer of diagnostic products, for exclusive worldwide use in a new diagnostic kit. TRANSTAT technology enables testing of blood or serum specimens in 5-10 minutes.
Key Takeaways:
- SangStat has commenced volume manufacturing of its TRANSTAT technology, a rapid cartridge-based testing system for haemostasis and coagulation testing.
- Diagnostica Stago S.A. has acquired exclusive worldwide rights to utilize TRANSTAT technology in a new diagnostic kit for testing D-Dimer levels, which are associated with serious coagulation disorders.
- SangStat will manufacture the kit cartridges for Stago on an exclusive basis, with Stago obligated to meet minimum purchase requirements and pay royalties on net sales.
- The agreement will help SangStat establish early commercial quantities of the TRANSTAT product line and generate near-term revenues, meeting two of its corporate objectives.
- SangStat is a biopharmaceutical company that has developed a range of therapeutic and monitoring products for organ transplantation, including 11 products and product candidates, with several in advanced stages of development.
Statistics:
- 5-10 minutes: the testing time enabled by TRANSTAT technology.
- 11: the number of products and product candidates developed by SangStat.
- 2: the number of corporate objectives met by the agreement with Diagnostica Stago S.A.
Sources:
- Business Wire, January 23, 1995
- SangStat Medical Corp.
- Diagnostica Stago S.A.